 |
|
|
| |
A Single Dose Food Effect Study of Raltegravir (RAL) Formulations Once Daily Tablet
|
| |
| |
Reported by Jules Levin
14th European AIDS Conference Oct 16-19 2013 Brussels, Belgium
Rajesh Krishna1, Matthew L. Rizk2, Valerie Schulz3, Benno Ingelse2, and Patrick Larson4
1Clinical Product Value Enhancement; 2Pharmacokinetics, Pharmacodynamics and Drug Metabolism; 3Early Development Operations; 4Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck & Co., Inc., Whitehouse Station, NJ
References
1. Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, et al; QDMRK Investigators. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011;(12):907-915.
2. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;857(1):15-24.
3. Brainard DM, Friedman EJ, Jin B, Breidinger SA, Tillan MD, Wenning LA, Stone JA, Chodakewitz JA, Wagner JA, Iwamoto M. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol. 2011;51(3):422-7.
|
| |
|
|
|
|
|
